https://www.biospace.com/pfizer-announces-the-lancet-neurology-has-published-phase-3-data-for-zavegepant-for-the-acute-treatment-of-migraine-in-adults
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute...
Feb 17, 2023 - Pfizer Inc. announced publication of results in The Lancet Neurology from the Phase 3 pivotal clinical trial of zavegepant, an investigational calcitonin...
the lancet neurology
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-lancet-neurology-has-published-phase-3
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute...
Zavegepant is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist in development as an intranasal formulation studied in a Phase 3...
the lancet neurology